These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
536 related articles for article (PubMed ID: 32146081)
1. Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab. Das S; Allen A; Berlin J Clin Colorectal Cancer; 2020 Jun; 19(2):137-140. PubMed ID: 32146081 [TBL] [Abstract][Full Text] [Related]
2. Paradigm shift from palliation to cure in metastatic microsatellite high colorectal carcinoma with immune checkpoint inhibitors. Dhamani AM; Sheth HS; Bhattacharyya S; Shaikh IN J Cancer Res Ther; 2021; 17(6):1552-1555. PubMed ID: 34916394 [TBL] [Abstract][Full Text] [Related]
3. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Thomas J; Leal A; Overman MJ Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280 [TBL] [Abstract][Full Text] [Related]
4. Improved first-line chemotherapy: a better chance for surgery? Tejpar S; Van Cutsem E; Adam R Lancet Oncol; 2010 Jan; 11(1):4-5. PubMed ID: 19942480 [No Abstract] [Full Text] [Related]
5. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. Gbolahan O; Hashemi-Sadraei N; O'Neil B J Natl Compr Canc Netw; 2019 Jun; 17(6):644-648. PubMed ID: 31200359 [TBL] [Abstract][Full Text] [Related]
6. Current Microsatellite Instability Testing in Management of Colorectal Cancer. Sun BL Clin Colorectal Cancer; 2021 Mar; 20(1):e12-e20. PubMed ID: 32888812 [TBL] [Abstract][Full Text] [Related]
7. A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination. Kitamura H; Koike S; Nakazawa K; Matsumura H; Yokoi K; Nakagawa K; Arai M J Surg Oncol; 2013 Feb; 107(2):155-9. PubMed ID: 22903532 [TBL] [Abstract][Full Text] [Related]
8. PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer. Pei F; He W; Duan Y; Yao Q; Zhao Y; Fan X; Liu S; Chen H; He F; Liu T; Chen J; Zheng Y; Li H; Guo X; Shi L; Ling L; Chen Y; He J; Liu M; Huang M; Bai Y; Wang J; Huang M; Huang J Cancer Med; 2024 Jun; 13(12):e7224. PubMed ID: 38888366 [TBL] [Abstract][Full Text] [Related]
9. In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. Malla SB; Fisher DJ; Domingo E; Blake A; Hassanieh S; Redmond KL; Richman SD; Youdell M; Walker SM; Logan GE; Chatzipli A; Amirkhah R; Humphries MP; Craig SG; McDermott U; Seymour MT; Morton DG; Quirke P; West NP; Salto-Tellez M; Kennedy RD; Johnston PG; Tomlinson I; Koelzer VH; Campo L; Kaplan RS; Longley DB; Lawler M; Maughan TS; Brown LC; Dunne PD; Clin Cancer Res; 2021 Jan; 27(1):288-300. PubMed ID: 33028592 [TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer. Oshima K; Yamazaki K Int J Clin Oncol; 2023 Nov; 28(11):1442-1450. PubMed ID: 37668816 [TBL] [Abstract][Full Text] [Related]
11. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer? Nipp RD; Ryan DP Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156 [TBL] [Abstract][Full Text] [Related]
12. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. Fernandes GDS; Braghiroli MI; Artioli M; Paterlini ACCR; Teixeira MC; Gumz BP; Girardi DDM; Braghiroli OFM; Costa FP; Hoff PM J Gastrointest Cancer; 2018 Dec; 49(4):470-475. PubMed ID: 28884286 [TBL] [Abstract][Full Text] [Related]
13. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective. Liu N; Shan F; Ma M Int Immunopharmacol; 2021 Oct; 99():108017. PubMed ID: 34352568 [TBL] [Abstract][Full Text] [Related]
14. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Mehrvarz Sarshekeh A; Overman MJ; Kopetz S Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436 [TBL] [Abstract][Full Text] [Related]
15. [Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis]. Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Inoue T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K Gan To Kagaku Ryoho; 2009 Nov; 36(12):2003-5. PubMed ID: 20037305 [TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer. Kasi PM; Budde G; Krainock M; Aushev VN; Koyen Malashevich A; Malhotra M; Olshan P; Billings PR; Aleshin A J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101943 [TBL] [Abstract][Full Text] [Related]
17. FOLFOXIRI and bevacizumab in metastatic colorectal cancer. Rahman A Lancet Oncol; 2014 Dec; 15(13):e590. PubMed ID: 25499288 [No Abstract] [Full Text] [Related]
18. Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver? Nordlinger B; Poston GJ; Goldberg RM J Clin Oncol; 2015 Jan; 33(3):241-3. PubMed ID: 25403221 [No Abstract] [Full Text] [Related]
19. Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer. Grothey A; Venook AP J Natl Compr Canc Netw; 2018 May; 16(5S):611-615. PubMed ID: 29784738 [TBL] [Abstract][Full Text] [Related]